Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
This announcement is significant because it signals the company's transition from regulatory approval to active market entry. With CE Mark certification already secured, Regentis is now focusing on the practical aspects of launching a medical device: ensuring that surgeons are trained and comfortable with the procedure. The training program at Humanitas Research Hospital, a renowned orthopedic center, lends credibility and could accelerate adoption among European surgeons.
The implications of this rollout are substantial. GelrinC addresses a large unmet need in knee cartilage repair. According to Regentis, approximately 470,000 cases for cartilage knee repair occur annually in the U.S. alone, where no off-the-shelf treatment is available. In Europe, the market is similarly underserved. GelrinC's cell-free, off-the-shelf nature eliminates the need for cell harvesting and culturing, potentially reducing procedure time and cost while making the treatment more accessible.
For Regentis, successful European commercialization could pave the way for future expansion into other markets, including the U.S., where the company would need FDA approval. The European launch will generate real-world clinical data and revenue that can support further development. It also validates the company's Gelrin platform technology, which is based on synchronized, degradable hydrogel implants that regenerate damaged tissue.
Investors and industry observers will be watching the training program's progress and subsequent adoption rates closely. For the full press release, visit https://ibn.fm/QOWWK. More information about Regentis and its technologies can be found on the InvestorBrandNetwork website, with disclaimers available at http://IBN.fm/Disclaimer.
